Can Practices Successfully Dispense Oral Anticancer Agents In-House?
In-house dispensing of oral agents in the community oncology setting may provide a safer and more reliable and convenient way for patients to receive their medications.
Treatment and Cost Implications of Pertuzumab
Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.
Developing Patient-Centered Medical Homes
Medical homes are physician-led healthcare teams that coordinate care for patients and typically rely on electronic methods for record-keeping, care coordination, and data collection.
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
Chemotherapy Followed by Endocrine Therapy Could Increase Cognitive Impairment in Breast Cancer, Irrespective of Menopausal Status
Racial Disparity Revealed in Prometastatic TME in Women With Residual Breast Cancer After Neoadjuvant Chemo
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.